Sugi Predict

Sugi Predict / Compounds / SCHEMBL120258

SCHEMBL120258

SCHEMBL120258

CC[C@@H](C)C1(CC)C(=O)NC(=S)NC1=O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.73
▸ PKM P14618 2/20 0.53
▸ POLB P06746 1/20 0.53
▸ CYP3A4 P08684 3/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ KDM4E B2RXH2 2/20 0.52
▸ GABRB3 P28472 1/20 0.52
▸ OPRD1 P41143 1/20 0.52
▸ GABRA2 P47869 1/20 0.52
▸ GABRB2 P47870 1/20 0.52
▸ MMP9 P14780 1/20 0.38
▸ NR1I2 O75469 1/20 0.37
▸ RECQL P46063 1/20 0.34
▸ MEN1 O00255 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ SIRT2 Q8IXJ6 1/20 0.32
▸ TSHR P16473 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL120257 1.00 LMNA (0.73) LMNAPKMPOLBCYP3A4ALDH1A1
SCHEMBL122120 0.98 LMNA (0.71) LMNAPKMPOLBCYP3A4ALDH1A1
SCHEMBL122119 0.98 LMNA (0.71) LMNAPKMPOLBCYP3A4ALDH1A1
Thiopental SCHEMBL1611312 0.85 LMNA (1.00) LMNAPKMPOLBCYP3A4ALDH1A1
Thiopental SCHEMBL40814 0.85 LMNA (1.00) LMNAPKMPOLBCYP3A4ALDH1A1
Butabarbital SCHEMBL79254 0.83 CYP3A4 (0.71) LMNAPKMPOLBCYP3A4ALDH1A1
Butabarbital SCHEMBL79255 0.83 CYP3A4 (0.71) LMNAPKMPOLBCYP3A4ALDH1A1
Butabarbital SCHEMBL122122 0.83 CYP3A4 (0.71) LMNAPKMPOLBCYP3A4ALDH1A1
Thiopental SCHEMBL6688973 0.83 LMNA (0.96) LMNAPKMPOLBCYP3A4ALDH1A1
SCHEMBL1263302 0.82 LMNA (0.65) LMNAPKMPOLBCYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 683 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240099995-A1 METHOD OF PREPARING A TOPICAL PHARMACEUTICAL COMPOSITION PHEBRA PTY LTD (AU) 2024-03-28 — — US claimed
EP-4291171-A1 METHOD OF PREPARING A TOPICAL PHARMACEUTICAL COMPOSITION Phebra Pty Ltd (AU) 2023-12-20 — — EP claimed
US-20170348303-A1 PHARMACEUTICAL COMPOSITIONS CHARLESTON LABORATORIES, INC. 2017-12-07 — — US claimed
US-20140030322-A1 PHARMACEUTICAL COMPOSITIONS LOCL PHARMA, INC. 2014-01-30 — — US claimed
US-20120201888-A1 Pharmaceutical Compositions CHARLESTON LABORATORIES, INC. (US) 2012-08-09 — — US claimed
EP-2240022-A2 PHARMACEUTICAL COMPOSITIONS Charleston Laboratories, Inc. (US) 2010-10-20 — — EP claimed
US-20100172916-A1 SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS AUSPEX PHARMACEUTICALS, INC. (US) 2010-07-08 — — US claimed
WO-2010054286-A2 SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS AUSPEX PHARMACEUTICALS, INC. (US) 2010-05-14 — — WO claimed
WO-2009089494-A2 PHARMACEUTICAL COMPOSITIONS CHARLESTON LABORATORIES, INC. (US) 2009-07-16 — — WO claimed
US-20090175939-A1 PHARMACEUTICAL COMPOSITIONS CHARLESTON LABORATORIES, INC. (US) 2009-07-09 — — US claimed
US-20050152957-A1 Compositions and delivery systems for administration of a local anesthetic agent CORIUM INTERNATIONAL (US) 2005-07-14 — — US claimed
US-20030027833-A1 Compositions and delivery systems for administration of a local anesthetic agent CORIUM INTERNATIONAL, INC. 2003-02-06 — — US claimed
WO-2002089849-A1 COMPOSITIONS AND DELIVERY SYSTEMS FOR ADMINISTRATION OF A LOCAL ANESTHETIC AGENT CORIUM INTERNATIONAL (US) 2002-11-14 — — WO claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 — — EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 — — WO claimed
EP-4736898-A2 NANOFIBER-HYDROGEL COMPOSITES FOR ENHANCED SOFT TISSUE REPLACEMENT AND REGENERATION The Johns Hopkins University (US) 2026-05-06 — — EP disclosed
EP-4729059-A2 THIAZOLO [5,4-B] PYRIDINE MALT-1 INHIBITORS Abbvie Inc. (US) 2026-04-22 — — EP disclosed
US-4183935-A ANTIARRHYTHMIA AGENTS BASF AKTIENGESELLSCHAFT (DE) 1980-01-15 — — US disclosed
EP-0000750-A1 1,2-Benzisothiazoles and process for their preparation BASF Aktiengesellschaft (DE) 1979-02-21 — — EP disclosed
EP-0000727-A1 3-(4-(1,3-Diazacycloalkene-2-yl)-phenyl)-1,2-benzisothiazoles, process for their preparation and medicaments containing them. BASF Aktiengesellschaft (DE) 1979-02-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100172916-A1 SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS MC1R, TYR, MITF LMNA 2644/4885PKM 553/4885POLB 2748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.